SPONTANEOUS FRACTURES IN A PATIENT TREATED WITH LOW-DOSES OF ETIDRONIC ACID (DISODIUM ETIDRONATE)

被引：15

作者：

EYRES, KS ^{[1
]}

MARSHALL, P ^{[1
]}

MCCLOSKEY, E ^{[1
]}

DOUGLAS, DL ^{[1
]}

KANIS, JA ^{[1
]}

机构：

[1] UNIV SHEFFIELD,DEPT HUMAN METAB & CLIN BIOCHEM,WHO,COLLABORATING CTR METAB BONE DIS,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND

来源：

DRUG SAFETY | 1992年 / 7卷 / 02期

关键词：

D O I：

10.2165/00002018-199207020-00008

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The recommended regimen of etidronic acid (disodium etidronate) for the treatment of Paget's disease of bone is 5mg/kg/day for a period of less than 6 months. There have, however, been reports of impaired mineralisation of bone and concern that the risk of fracture is increased with this dosage. We report a patient with Paget's disease in whom fractures occurred through pagetic and non-pagetic bone which appeared to be causally related to treatment with low doses of etidronic acid. The osteomalacia resolved when etidronic acid was discontinued.

引用

页码：162 / 165

页数：4

共 16 条

[1]

Alexandre C., Meunier P.J., Edourd C., Khairi R.A., Johnston C.C., Effects of EHDP (5mg/Kg/day dose) on quantitative bone histology in Paget’s disease of bone, Metabolic Bone Disease and Related Research, 3, pp. 309-315, (1981)

[2]

Altman R.D., Johnston C.C., Khairi A., Wellman H., Serafini A.N., Et al., Influence of disodium etidronic acid on clinical and laboratory manifestations of Paget’s disease of bone, New England Journal of Medicine, 289, pp. 1379-1384, (1973)

[3]

Boyce B.F., Fogelman I., Ralston S., Smith L., Johnston E., Et al., Focal osteomalacia due to low-dose diphosphonate therapy in Paget’s disease, Lancet, 1, pp. 821-824, (1984)

[4]

Canfield R., Rosner W., Skinner J., McWhorter J., Resnick L., Et al., Diphosphonate therapy of Paget’s disease of bone, Journal of Clinical Endocrinology and Metabolism, 44, pp. 96-106, (1977)

[5]

Fogelman I., Smith M., Mazess R., Wilson M.A., Bevan J.A., Absorption of oral diphosphonates in normal subjects, Clinical Endocrinology, 24, pp. 57-68, (1986)

[6]

Frijlink W.B., Bijvoet O.L., Tevelde J., Heynen G., Treatment of Paget’s disease with 3-amino-l-hydroxypropylidene-l, 1-bisphosphonate: APD, Lancet, 1, pp. 799-803, (1979)

[7]

Fromm G., Schajowicz F., Mautelen C.A., Disodium ethane-1-hydroxy, 1-diphosphonate (EHDP) in Paget’s disease, Lancet, 2, (1975)

[8]

Johnston C.C., Altman R.D., Canfield R.E., Finerman G.A.M., Taulbee J.D., Et al., Review of fracture experience during treatment of Paget’s disease of bone with etidronate disodium (EHDP), Clinical Orthopaedics and Related Research, 172, pp. 186-194, (1983)

[9]

Kanis J.A., Evanson J.M.E., Russell R.G.G., Paget’s disease of bone, Diagnosis and management. Metabolic Bone Disease and Related Research, 3, pp. 219-230, (1981)

[10]

Kantrowitz F.G., Byrne M.H., Schiller A.L., Krane S.M., Clinical and biochemical effects of diphosphonates in Paget’s disease of bone, Arthritis and Rheumatism, 18, (1975)

← 1 2 →